We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
French pharma company Ipsen has entered into a new collaboration agreement with BAKX Therapeutics focused on an oral small-molecule activator of BAX for the potential treatment of leukaemia, lymphoma and solid tumours.